We are live on ! Find out more
ABVC icon

ABVC BioPharma
ABVC

13 hedge funds and large institutions have $792K invested in ABVC BioPharma in 2026 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 6

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

0.31% less ownership

Funds ownership: 3.52% → 3.21% (-0.31%)

7% less funds holding

Funds holding: 14 → 13 (-1)

57% less capital invested

Capital invested by funds: $1.82M → $792K (-$1.03M)

Holders
13
Holders Change
-1
Holders Change %
-7.14%
% of All Funds
0.16%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
2
Reduced
2
Closed
6
Calls
$10K
Puts
–
Net Calls
+$10K
Net Calls Change
+$53K

Top Buyers

Rank Fund Capital Flow
1
TSS
Two Sigma Securities
New York
+$34.8K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$31.1K
3
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$20.2K
4
Squarepoint
Squarepoint
New York
+$17.4K
5
TRCT
Tower Research Capital (TRC)
New York
+$3.69K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$118K
2
Renaissance Technologies
Renaissance Technologies
New York
-$31.7K
3
XT
XTX Topco
Cayman Islands
-$24K
4
Jane Street
Jane Street
New York
-$18K
5
Morgan Stanley
Morgan Stanley
New York
-$11K
Name Holding Trade Value Shares
Change 		Change in
Stake
Geode Capital Management
1
Geode Capital Management
Massachusetts
$215K +$31.1K +18,804 +9%
VCM
2
Vanguard Capital Management
Pennsylvania
$185K +$315K +190,574 New
VFT
3
Vanguard Fiduciary Trust
Pennsylvania
$94.4K +$161K +97,363 New
Renaissance Technologies
4
Renaissance Technologies
New York
$92.3K -$31.7K -19,163 -17%
State Street
5
State Street
Massachusetts
$70.6K – – –
BlackRock
6
BlackRock
New York
$54.8K – – –
Northern Trust
7
Northern Trust
Illinois
$31.1K – – –
TSS
8
Two Sigma Securities
New York
$20.4K +$34.8K +21,023 New
Dimensional Fund Advisors
9
Dimensional Fund Advisors
Texas
$11.9K +$20.2K +12,227 New
Squarepoint
10
Squarepoint
New York
$10.2K +$17.4K +10,547 New
TRCT
11
Tower Research Capital (TRC)
New York
$5.26K +$3.69K +2,230 +70%
UBS Group
12
UBS Group
Switzerland
$1.72K -$1.35K -817 -32%
Citadel Advisors
13
Citadel Advisors
Florida
– -$118K -55,543 Closed
XT
14
XTX Topco
Cayman Islands
– -$24K -11,261 Closed
Jane Street
15
Jane Street
New York
– -$18K -10,867 Closed
Morgan Stanley
16
Morgan Stanley
New York
– -$11K -5,175 Closed
Simplex Trading
17
Simplex Trading
Illinois
– -$417 -196 Closed
Bank of America
18
Bank of America
North Carolina
– -$402 -189 Closed
Royal Bank of Canada
19
Royal Bank of Canada
Ontario, Canada
– +$28 +17 New

ABVC Hedge Fund Activity: Q1 2026 in Review

13 of the 8,130 institutional investors tracked by Wall St. Rank reported a position in ABVC BioPharma (ABVC) for Q1 2026, worth a combined $792K — down 57% from $1.82M a quarter earlier.

Fund positioning in ABVC was balanced in Q1 2026: 6 funds opened new positions, 6 closed out, 2 added to existing stakes and 2 trimmed.

The largest buyer was Two Sigma Securities, opening a new position worth an estimated $34.8K. The largest seller was Citadel Advisors, exiting entirely with an estimated $118K sold.

  • 13 institutional investors held ABVC BioPharma (ABVC) as of Q1 2026, down from 14 in Q4 2025.
  • Funds reported $792K of ABVC BioPharma stock for Q1 2026, down 57% quarter-over-quarter.
  • 6 funds opened new ABVC BioPharma positions in Q1 2026 and 6 closed out, a net change of 0 holders.
  • The largest ABVC BioPharma buyer in Q1 2026 was Two Sigma Securities, an estimated $34.8K added.
  • The largest ABVC BioPharma seller in Q1 2026 was Citadel Advisors, an estimated $118K sold.

Based on aggregated 13F filings for Q1 2026.